WESTBROOK, Maine, Jan. 8, 2018 /PRNewswire/ — IDEXX Laboratories, Inc. (NASDAQ: IDXX) and Applied BioCode (6598:Taipei) today announced that they have entered into an exclusive global agreement to bring Applied BioCode’s digital multiplex platform to IDEXX Reference Laboratories customers. IDEXX anticipates the technology will be commercially available starting in 2019. Applied BioCode is a California-headquartered diagnostics company that designs, develops, manufactures, and markets systems for highly multiplexed assays.
“IDEXX’s market-leading innovation is at the core of our strategy,” said Jonathan Ayers, Chairman and Chief Executive Officer of IDEXX Laboratories. “Implementation of Applied BioCode’s technology supports our vision for margin expansion, and it will allow us to offer customers expanded test menu breadth and menu customization for each patient sample submitted to IDEXX Reference Laboratories in the future. This is consistent with our commitment to provide the most comprehensive, cost-effective, and timely diagnostic picture for our customers and their patients. This proprietary technology platform will also likely have applications in our other animal health diagnostic markets.”
Paired with IDEXX’s proprietary assays and reagents, Applied BioCode’s technology enables the development of an ultra-high sensitivity immunoassay platform. Immunoassay is the detection technology used on platforms such as IDEXX SNAP® tests for applications as diverse as vector-borne disease and parasitology as well as for both sick and preventive care uses.
“Applied BioCode is thrilled to introduce our technology to veterinary medicine with IDEXX, enabling veterinarians to benefit from our advanced multiplexing capabilities,” said Winston Ho, President of Applied BioCode. “We look forward to working with the IDEXX team to implement our platform at its reference laboratories.”
For more information about IDEXX Reference Laboratories, visit www.idexx.com.